Literature DB >> 11163832

Microsatellite DNA assays reveal an allelic imbalance in p16(Ink4), GALT, p53, and APOA2 loci in patients with endometriosis.

A G Goumenou1, D A Arvanitis, I M Matalliotakis, E E Koumantakis, D A Spandidos.   

Abstract

OBJECTIVE: To detect allelic imbalance on specific genetic loci occurring in endometriosis.
DESIGN: Microsatellite analysis.
SETTING: Paraffin-embedded tissues histologically confirmed as endometriotic or normal endometrium. PATIENT(S): Premenopausal women undergoing laparoscopy for suspected endometriosis. INTERVENTION(S): Laparoscopic excision of specimens. MAIN OUTCOME MEASURE(S): Allelic imbalance and alterations of intensity of microsatellite alleles. RESULT(S): Five of 17 microsatellite DNA markers (29.4%) showed allelic imbalance. Eight samples (36.4%) showed allelic imbalance in at least one locus. Loci 9p21, 1q21, and 17p13.1 exhibited imbalance in 27.3%, 4.5%, and 4.5%, respectively. A 3-fold increase of the fractional allelic loss was observed from disease stage II to III and IV, whereas only 1.3-fold was found between patients of 41-50 and 20-40 years. CONCLUSION(S): We found that loss of heterozygosity on p16(Ink4), GALT, and p53, as well as on APOA2, a region frequently lost in ovarian cancer, occurs in endometriosis, even in stage II of the disease. The occurrence of such genomic alterations may represent important events in the development of endometriosis. The 9p21 locus may contain a gene associated with the pathogenesis of the disease, and therefore its loss may be a prognostic marker of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163832     DOI: 10.1016/s0015-0282(00)01663-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

1.  Genomic rearrangements on VCAM1, SELE, APEG1and AIF1 loci in atherosclerosis.

Authors:  D A Arvanitis; G A Flouris; D A Spandidos
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

2.  Endometriosis research using capture microdissection techniques: Progress and future applications.

Authors:  Luyang Zhao; Chenglei Gu; Ke Huang; Weidong Han; Meng Fu; Yuanguang Meng
Journal:  Biomed Rep       Date:  2016-09-15

3.  Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French women.

Authors:  Marina Kvaskoff; Sylvie Mesrine; Agnès Fournier; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon
Journal:  Arch Intern Med       Date:  2007-10-22

Review 4.  Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.

Authors:  Paul J Yong; Aline Talhouk; Michael S Anglesio
Journal:  Reprod Sci       Date:  2021-01-19       Impact factor: 3.060

5.  Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development.

Authors:  Chengquan Zhao; Lee Shu-Fune Wu; Ross Barner
Journal:  J Cancer       Date:  2011-02-21       Impact factor: 4.207

6.  Endometriosis and ovarian cancer: a systematic review.

Authors:  Ahmad Sayasneh; Dimitris Tsivos; Robin Crawford
Journal:  ISRN Obstet Gynecol       Date:  2011-07-15

7.  Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases.

Authors:  Daniel E Machado; Plínio T Berardo; Celia Y Palmero; Luiz E Nasciutti
Journal:  J Exp Clin Cancer Res       Date:  2010-01-19

8.  Bioinformatics profiling identifies seven immune-related risk signatures for hepatocellular carcinoma.

Authors:  Feng Xue; Lixue Yang; Binghua Dai; Hui Xue; Lei Zhang; Ruiliang Ge; Yanfu Sun
Journal:  PeerJ       Date:  2020-05-26       Impact factor: 2.984

Review 9.  Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis.

Authors:  Sun-Wei Guo
Journal:  Reprod Med Biol       Date:  2018-08-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.